Early Phase 1 psychedelic research trials
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Early Phase 1 is a registry phase value. Exploratory first-in-human work that happens before a standard Phase 1 study. A phase describes how a study is designed, not what it found.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 64 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 23 |
| MDMA | 8 |
| LSD | 7 |
| DMT | 2 |
| Ayahuasca | 1 |
| Ketamine | 26 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 15 | 23% |
| Not yet recruiting | 3 | 5% |
| Active, not recruiting | 4 | 6% |
| Completed | 28 | 44% |
| Terminated | 1 | 2% |
| Suspended | 2 | 3% |
| Withdrawn | 5 | 8% |
| Status not reported | 6 | 9% |
Countries
Country is taken from the study's linked research site. 4 of 64 records have no country on file. The top 9 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 40 | 63% |
| Switzerland | 11 | 17% |
| China | 2 | 3% |
| United Kingdom | 2 | 3% |
| Brazil | 1 | 2% |
| Canada | 1 | 2% |
| Denmark | 1 | 2% |
| Ireland | 1 | 2% |
| Israel | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 20 |
| 2020 to 2023 | 25 |
| 2015 to 2019 | 12 |
| 2010 to 2014 | 6 |
| Before 2010 | 1 |
Study design
- 64 interventional and 0 observational studies.
- Median planned or actual enrolment is 26 participants (range 2 to 500, across 60 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 13 |
| Cancer and end of life | 8 |
| Other substance use | 6 |
| Anxiety | 5 |
| Suicidal thoughts | 4 |
| Pain and headache | 3 |
| Healthy volunteers | 3 |
| Trauma and PTSD | 2 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07565493 | Psilocybin Administration With 5-HT1a Blockade | Recruiting | Early Phase 1 | United States | 2026-06 |
| NCT06066853 | MDMA-assisted Therapy for Fibromyalgia | Recruiting | Early Phase 1 | United States | 2026-04 |
| NCT07449351 | Psilocybin Microdosing on Cognition, Mood and Quality of Life | Not yet recruiting | Early Phase 1 | United States | 2026-04 |
| NCT07732166 | Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin. | Recruiting | Early Phase 1 | Brazil | 2026-04 |
| NCT06378528 | Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP) | Suspended | Early Phase 1 | United States | 2026-03 |
| NCT06724289 | Psilocybin for Prolonged Grief Disorder | Recruiting | Early Phase 1 | United States | 2026-03 |
| NCT06102434 | Safety Profile of Psilocybin for Cocaine Use Disorder | Suspended | Early Phase 1 | United States | 2026-02 |
| NCT06788249 | Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine | Recruiting | Early Phase 1 | United States | 2026-02 |
| NCT07247968 | Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study | Recruiting | Early Phase 1 | China | 2025-11 |
| NCT06798636 | PsiloIMAGINE: A Psychedelic-augmented Mental Imagery-based Intervention for Young People With Self-harm | Recruiting | Early Phase 1 | United Kingdom | 2025-10 |
| NCT07118332 | Psilocybin as a Treatment for Chronic Pain in Smokers | Recruiting | Early Phase 1 | United States | 2025-10 |
| NCT06760533 | Psilocybin-Assisted Psychotherapy in Treating Irritable Bowel Syndrome (IBS) | Not yet recruiting | Early Phase 1 | United States | 2025-08 |
| NCT07737054 | Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for PTSD | Recruiting | Early Phase 1 | Israel | 2025-07 |
| NCT07061886 | Drug Effects on Mood and Behavior - Expectancy | Completed | Early Phase 1 | United States | 2025-06 |
| NCT07017478 | Mood Effects of Serotonin Agonists: Depression | Completed | Early Phase 1 | United States | 2025-06 |
| NCT06464367 | Mechanistic Studies of Psilocybin in Headache Disorders | Recruiting | Early Phase 1 | United States | 2025-05 |
| NCT06656702 | Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis | Recruiting | Early Phase 1 | United States | 2025-04 |
| NCT06899594 | Psilocybin for Methamphetamine Addiction | Recruiting | Early Phase 1 | United States | 2025-04 |
| NCT06665568 | Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients | Not yet recruiting | Early Phase 1 | Switzerland | 2025-04 |
| NCT06565494 | MDMA-Assisted Therapy for Pathological Narcissism | Active, not recruiting | Early Phase 1 | United States | 2024-08 |
| NCT05953038 | LSD Occupancy of the Serotonin 2A Receptor in the Human Brain | Active, not recruiting | Early Phase 1 | Denmark | 2023-11 |
| NCT05068791 | Psilocybin-facilitated Treatment for Chronic Pain | Recruiting | Early Phase 1 | United States | 2023-11 |
| NCT05344625 | Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress | Withdrawn | Early Phase 1 | United States | 2023-10 |
| NCT06073015 | Effect of Esketamine on Reducing Postoperative Anxiety and Depression in Adolescent Patients | Status not reported | Early Phase 1 | Not reported | 2023-10 |
| NCT05958758 | A Community of Practice Program With Psilocybin-assisted Therapy for End-of-Life Patients | Status not reported | Early Phase 1 | Not reported | 2023-09 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable